230,000 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Vestal Point Capital LP

Vestal Point Capital LP acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the 3rd quarter, Holdings Channel reports. The institutional investor acquired 230,000 shares of the company’s stock, valued at approximately $7,565,000.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock worth $66,398,000 after acquiring an additional 231,131 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Tarsus Pharmaceuticals in the first quarter valued at $12,640,000. Janus Henderson Group PLC bought a new position in shares of Tarsus Pharmaceuticals in the first quarter valued at about $313,000. Assenagon Asset Management S.A. acquired a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth about $28,904,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Tarsus Pharmaceuticals by 27.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 122,634 shares of the company’s stock worth $3,333,000 after buying an additional 26,225 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Up 2.4 %

Shares of TARS stock opened at $50.84 on Friday. The stock has a 50 day simple moving average of $40.37 and a 200 day simple moving average of $33.19. Tarsus Pharmaceuticals, Inc. has a 1 year low of $15.60 and a 1 year high of $52.99. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on TARS shares. The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $54.20.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.